Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
[ Ra]RaCl is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [ Ra]RaCl is excreted via the intestine into feces, and some is absorbed from the intestine into the bloo...
Saved in:
Published in | Scientific reports Vol. 10; no. 1; p. 11917 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Nature Publishing Group
17.07.2020
Nature Publishing Group UK |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | [
Ra]RaCl
is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [
Ra]RaCl
is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of myo-inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [
Ra]RaCl
after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82 ± 1.83%Dose/g) than the mice in the non-treatment control group (40.30 ± 2.78%Dose/g) at 48 h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [
Ra]RaCl
. |
---|---|
AbstractList | [223Ra]RaCl2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [223Ra]RaCl2 is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of myo-inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [223Ra]RaCl2 after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82 ± 1.83%Dose/g) than the mice in the non-treatment control group (40.30 ± 2.78%Dose/g) at 48 h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [223Ra]RaCl2. Abstract [ 223 Ra]RaCl 2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [ 223 Ra]RaCl 2 is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of myo -inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [ 223 Ra]RaCl 2 after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82 ± 1.83%Dose/g) than the mice in the non-treatment control group (40.30 ± 2.78%Dose/g) at 48 h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [ 223 Ra]RaCl 2 . [ Ra]RaCl is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [ Ra]RaCl is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of myo-inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [ Ra]RaCl after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82 ± 1.83%Dose/g) than the mice in the non-treatment control group (40.30 ± 2.78%Dose/g) at 48 h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [ Ra]RaCl . [ 223 Ra]RaCl 2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [ 223 Ra]RaCl 2 is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of myo -inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [ 223 Ra]RaCl 2 after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82 ± 1.83%Dose/g) than the mice in the non-treatment control group (40.30 ± 2.78%Dose/g) at 48 h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [ 223 Ra]RaCl 2 . |
ArticleNumber | 11917 |
Author | Shiba, Kazuhiro Kinuya, Seigo Odani, Akira Ogawa, Kazuma Mishiro, Kenji Wakabayashi, Hiroshi Higashi, Takuma |
Author_xml | – sequence: 1 givenname: Kazuma surname: Ogawa fullname: Ogawa, Kazuma email: kogawa@p.kanazawa-u.ac.jp, kogawa@p.kanazawa-u.ac.jp organization: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. kogawa@p.kanazawa-u.ac.jp – sequence: 2 givenname: Takuma surname: Higashi fullname: Higashi, Takuma organization: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan – sequence: 3 givenname: Kenji surname: Mishiro fullname: Mishiro, Kenji organization: Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan – sequence: 4 givenname: Hiroshi surname: Wakabayashi fullname: Wakabayashi, Hiroshi organization: Kanazawa University Hospital, Takara-machi, Kanazawa, 920-8641, Japan – sequence: 5 givenname: Kazuhiro surname: Shiba fullname: Shiba, Kazuhiro organization: Advanced Science Research Center, Kanazawa University, Takara-machi, Kanazawa, 920-8640, Japan – sequence: 6 givenname: Akira surname: Odani fullname: Odani, Akira organization: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan – sequence: 7 givenname: Seigo surname: Kinuya fullname: Kinuya, Seigo organization: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32681007$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUdtqXSEUlJLSpGl-oA9F6PNuvW99KZT0CoG-5F10u8wxnK2pukv6Cf3rmpw0pCK4wJlZs9a8REe5ZEDoNSXvKOH6fRNUGj0RRialtVDT7TN0woiQE-OMHT2pj9FZa9dkHMmMoOYFOuZMaUrIfIL-fIKlgmspX-EtB2ipOr8H7Hwr1UPA1YXkeioZ94L7DnDKHVpPeWBih4pdWFNOrdcDqsR7yrZOjHEc0rLbl5oC4Fgq7qNVXyH3O5gfA-EVumvjQnuFnke3b3D28J6iyy-fL8-_TRc_vn4__3gxLXI2fWIGAo2SEWK4MmOoKExUYWYUuIwAgjIB1HivqNdm0XKJswnRc-d1ZJKfog8H2ZvNrxCWYaa6vb2paXX1ty0u2f9_ctrZq_LLzlzpsfgh8PZBoJaf21iFvS5bzcOyZYIJqZSh80CxA2qppbUK8bEDJfYuQHsI0I4A7X2A9naQ3jz19kj5Fxf_C8ymnDI |
CitedBy_id | crossref_primary_10_3389_fmed_2022_1059122 crossref_primary_10_1016_j_ijpharm_2023_123765 |
Cites_doi | 10.4162/nrp.2009.3.1.15 10.1093/jn/137.4.1101 10.2172/751062 10.1371/journal.pone.0195067 10.2174/092986712801215865 10.1080/13590840020030267 10.2967/jnumed.115.157123 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 10.1371/journal.pone.0148080 10.1158/1078-0432.CCR-04-2244 10.1007/s12149-016-1093-8 10.2307/3579805 10.1155/2015/676053 10.1038/nsmb1105-940 10.1248/cpb.c16-00792 10.1016/j.icrp.2006.03.001 10.1089/jmf.2007.0075 10.1007/s00259-013-2427-6 10.1016/j.clgc.2017.10.022 10.1016/S1470-2045(14)70474-7 10.1042/bj0830025 10.1111/j.1439-0396.2005.00532.x 10.1016/j.ijrobp.2019.07.022 10.1016/S1567-5769(03)00082-1 10.1016/0002-9343(62)90185-7 10.1016/0891-5849(90)90146-A 10.1056/NEJMoa1213755 10.1016/j.ccr.2007.09.008 10.1093/jn/129.9.1731 10.1007/BF02901539 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
Copyright_xml | – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI PRINS Q9U 5PM |
DOI | 10.1038/s41598-020-68846-x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
ExternalDocumentID | 10_1038_s41598_020_68846_x 32681007 |
Genre | Journal Article |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAADF AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ADBBV ADRAZ AENEX AFGXO AFKRA AFPKN AJTQC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF DIK DWQXO EBD EBS ECM EIF ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO NPM OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP AAYXX ALIPV C6C CITATION EBLON 7XB 8FK K9. PQEST PQUKI PRINS Q9U 5PM |
ID | FETCH-LOGICAL-c579t-29ed1f52009369000f49f6d721e35fee4124e19bb61b89c85cf79dfb3ab8f253 |
IEDL.DBID | RPM |
ISSN | 2045-2322 |
IngestDate | Tue Sep 17 21:26:39 EDT 2024 Fri Sep 13 08:18:00 EDT 2024 Fri Aug 23 01:56:17 EDT 2024 Thu May 23 23:27:40 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c579t-29ed1f52009369000f49f6d721e35fee4124e19bb61b89c85cf79dfb3ab8f253 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368038/ |
PMID | 32681007 |
PQID | 2424566917 |
PQPubID | 2041939 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7368038 proquest_journals_2424566917 crossref_primary_10_1038_s41598_020_68846_x pubmed_primary_32681007 |
PublicationCentury | 2000 |
PublicationDate | 2020-07-17 |
PublicationDateYYYYMMDD | 2020-07-17 |
PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-17 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Scientific reports |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2020 |
Publisher | Nature Publishing Group Nature Publishing Group UK |
Publisher_xml | – name: Nature Publishing Group – name: Nature Publishing Group UK |
References | E Graf (68846_CR16) 1983; 60 JA Shim (68846_CR15) 2009; 3 KM Hambidge (68846_CR32) 2007; 137 RP Singh (68846_CR31) 2005; 25 K Ogawa (68846_CR2) 2012; 19 F Crea (68846_CR19) 2008; 252 JA Carrasquillo (68846_CR23) 2013; 40 E Graf (68846_CR18) 1990; 8 S Nilsson (68846_CR5) 2005; 11 SA Fry (68846_CR26) 1998; 150 P Hoskin (68846_CR4) 2014; 15 J Mercola (68846_CR12) 2001; 11 K Ogawa (68846_CR9) 2017; 65 K Ogawa (68846_CR3) 2015; 2015 T Szkudelski (68846_CR17) 2005; 89 ML Queiroz (68846_CR13) 2003; 3 68846_CR28 C Parker (68846_CR22) 2013; 369 K Ogawa (68846_CR10) 2018; 13 J Taprogge (68846_CR21) 2019; 105 ND Shore (68846_CR24) 2018; 16 D Scadden (68846_CR30) 2005; 12 SJ Chittenden (68846_CR6) 2015; 56 K Ogawa (68846_CR8) 2016; 11 68846_CR20 JY Shim (68846_CR14) 2008; 11 RE Coleman (68846_CR1) 1997; 80 K Morita (68846_CR11) 1999; 129 HQ Woodard (68846_CR25) 1962; 32 Alkaline Earth Metabolism in Adult Man (68846_CR27) 1973 K Yoshida (68846_CR29) 2016; 30 DM Taylor (68846_CR7) 1962; 83 |
References_xml | – volume: 3 start-page: 15 year: 2009 ident: 68846_CR15 publication-title: Nutr. Res. Pract. doi: 10.4162/nrp.2009.3.1.15 contributor: fullname: JA Shim – volume: 137 start-page: 1101 year: 2007 ident: 68846_CR32 publication-title: J. Nutr. doi: 10.1093/jn/137.4.1101 contributor: fullname: KM Hambidge – ident: 68846_CR28 doi: 10.2172/751062 – volume-title: ICRP Publication 20 year: 1973 ident: 68846_CR27 contributor: fullname: Alkaline Earth Metabolism in Adult Man – volume: 13 start-page: e0195067 year: 2018 ident: 68846_CR10 publication-title: PLoS ONE doi: 10.1371/journal.pone.0195067 contributor: fullname: K Ogawa – volume: 19 start-page: 3290 year: 2012 ident: 68846_CR2 publication-title: Curr. Med. Chem. doi: 10.2174/092986712801215865 contributor: fullname: K Ogawa – volume: 11 start-page: 53 year: 2001 ident: 68846_CR12 publication-title: J. Nutr. Environ. Med. doi: 10.1080/13590840020030267 contributor: fullname: J Mercola – volume: 56 start-page: 1304 year: 2015 ident: 68846_CR6 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.115.157123 contributor: fullname: SJ Chittenden – volume: 80 start-page: 1588 year: 1997 ident: 68846_CR1 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G contributor: fullname: RE Coleman – volume: 11 start-page: e0148080 year: 2016 ident: 68846_CR8 publication-title: PLoS ONE doi: 10.1371/journal.pone.0148080 contributor: fullname: K Ogawa – volume: 25 start-page: 2891 year: 2005 ident: 68846_CR31 publication-title: Anticancer Res. contributor: fullname: RP Singh – volume: 11 start-page: 4451 year: 2005 ident: 68846_CR5 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-04-2244 contributor: fullname: S Nilsson – volume: 30 start-page: 453 year: 2016 ident: 68846_CR29 publication-title: Ann. Nucl. Med. doi: 10.1007/s12149-016-1093-8 contributor: fullname: K Yoshida – volume: 150 start-page: S21 year: 1998 ident: 68846_CR26 publication-title: Radiat Res doi: 10.2307/3579805 contributor: fullname: SA Fry – volume: 2015 start-page: 676053 year: 2015 ident: 68846_CR3 publication-title: Biomed. Res. Int. doi: 10.1155/2015/676053 contributor: fullname: K Ogawa – volume: 12 start-page: 940 year: 2005 ident: 68846_CR30 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb1105-940 contributor: fullname: D Scadden – volume: 65 start-page: 261 year: 2017 ident: 68846_CR9 publication-title: Chem. Pharm. Bull. (Tokyo) doi: 10.1248/cpb.c16-00792 contributor: fullname: K Ogawa – ident: 68846_CR20 doi: 10.1016/j.icrp.2006.03.001 – volume: 11 start-page: 479 year: 2008 ident: 68846_CR14 publication-title: J. Med. Food doi: 10.1089/jmf.2007.0075 contributor: fullname: JY Shim – volume: 40 start-page: 1384 year: 2013 ident: 68846_CR23 publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-013-2427-6 contributor: fullname: JA Carrasquillo – volume: 16 start-page: 149 year: 2018 ident: 68846_CR24 publication-title: Clin. Genitourin. Cancer doi: 10.1016/j.clgc.2017.10.022 contributor: fullname: ND Shore – volume: 15 start-page: 1397 year: 2014 ident: 68846_CR4 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)70474-7 contributor: fullname: P Hoskin – volume: 83 start-page: 25 year: 1962 ident: 68846_CR7 publication-title: Biochem. J. doi: 10.1042/bj0830025 contributor: fullname: DM Taylor – volume: 89 start-page: 397 year: 2005 ident: 68846_CR17 publication-title: J. Anim. Physiol. Anim. Nutr. (Berl) doi: 10.1111/j.1439-0396.2005.00532.x contributor: fullname: T Szkudelski – volume: 105 start-page: 884 year: 2019 ident: 68846_CR21 publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2019.07.022 contributor: fullname: J Taprogge – volume: 3 start-page: 889 year: 2003 ident: 68846_CR13 publication-title: Int. Immunopharmacol. doi: 10.1016/S1567-5769(03)00082-1 contributor: fullname: ML Queiroz – volume: 32 start-page: 96 year: 1962 ident: 68846_CR25 publication-title: Am. J. Med. doi: 10.1016/0002-9343(62)90185-7 contributor: fullname: HQ Woodard – volume: 8 start-page: 61 year: 1990 ident: 68846_CR18 publication-title: Free Radic. Biol. Med. doi: 10.1016/0891-5849(90)90146-A contributor: fullname: E Graf – volume: 369 start-page: 213 year: 2013 ident: 68846_CR22 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1213755 contributor: fullname: C Parker – volume: 252 start-page: 1108 year: 2008 ident: 68846_CR19 publication-title: Coord. Chem. Rev. doi: 10.1016/j.ccr.2007.09.008 contributor: fullname: F Crea – volume: 129 start-page: 1731 year: 1999 ident: 68846_CR11 publication-title: J. Nutr. doi: 10.1093/jn/129.9.1731 contributor: fullname: K Morita – volume: 60 start-page: 1861 year: 1983 ident: 68846_CR16 publication-title: J. Am. Oil Chem. Soc. doi: 10.1007/BF02901539 contributor: fullname: E Graf |
SSID | ssj0000529419 |
Score | 2.3576736 |
Snippet | [
Ra]RaCl
is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of... Abstract [ 223 Ra]RaCl 2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone... [223Ra]RaCl2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because... [ 223 Ra]RaCl 2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 11917 |
SubjectTerms | Absorption, Radiation Administration, Oral Animals Bone cancer Bone Neoplasms - drug therapy Bone Neoplasms - secondary Castration Cations Chlorella - metabolism Hydrogen-Ion Concentration Inositol Intestine Intestines - radiation effects Intravenous administration Male Metastases Metastasis Mice Pharmaceuticals Phytic Acid - chemistry Phytic Acid - metabolism Prostate cancer Radioactivity Radioisotopes Radioisotopes - administration & dosage Radioisotopes - therapeutic use Radium Radium - administration & dosage Radium - therapeutic use Strontium Tissue Distribution Zinc - pharmacology |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwEB1tWVXqpeKr7QKtfOBWWUu-7ROCFrSqBEIVSNyi2B6LPbCBTZDgJ_CvmXGyC9tKnOPYSZ7jefbMvAHYjzyRiji2srBFJdPMZVIRC5FJmlvlURcYFG_OzvPJVfrnOrsewGSRC8NhlYs1MSzUrrZ8Rj6Og4sup93FuDJ8CmDb8eHdveT6Uexn7YtpfIBhHKXssB0en5xf_F2et7BHK410nzdzkKhxQ7aL88t4_6TIDMvHVdv0H-H8N27yjSE6XYfPPYMURx3kGzDA2SZ87GpKPm3B8-9ABPkIQHCCWDOdc3aUoNep5wadmLMaAcMh2loQ_ROsGEE_-ozacMFwUa3o6Yrah1sebiXZeOGm9oaD9hwKortiGafOzUxNfdxiWxHjbLDZhsvTk8tfE9nXW5A2K3QrY40u8kGHKcm5mKhPtc8d7RExyTwiF6rGSBuTR0ZpqzLrC-28SSqjfJwlX2BtRgN9A1FF6IhMOXuAxHgw1pUj8BXSALSeWBzBz8WHLu86VY0yeMMTVXawlARLGWApH0ewt8Ci7P-wpnydDyP42sGy7IooqeLojxEUK4AtG7Cm9uqV2fQmaGsXSa7oKXbeH3IXPsU8b4LA5h6stfMH_E7kpDU_-nn3AlXD6Go priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA6iCF7Et-uLHLxJ1Kav5CAiPhBBTwreSpNMcEF3te2C_gT_tTNpd3FVPDfJlHxJ50sz8w1j-5FHUiGlFbnNS5GkLhUKWYiIk8wqDzqHoHhze5ddPyQ3j-njDBuXO-omsP7zaEf1pB6q58P3t49T3PAnbcq4OqrRCVGiGB2EFPpTgZxyTiZojkL5Orrfan1LnUS6y535u-u0f_pFOn_GTn5zRldLbLFjkfyshX2ZzcBghc23dSU_VtnnRSCD9BuAU5JY3a8oQ4qXph5WBhyvSJGAIOHNkCMF5KQagZt9gG2oaDgvpzR1-dCHLqMXgX6eu759osA9BxwpL5_EqlMzM8QxXqApkXXWUK-x-6vL-_Nr0dVcEDbNdSOkBhf5oMUUZ1RQ1CfaZw7PiRCnHoCKVUOkjckio7RVqfW5dt7EpVFepvE6mx2goU3GywgcEipnjwFZD0hdOkREARrAb4qFHjsYT3Tx2iprFOFGPFZFC0uBsBQBluK9x3bGWBTjRVLIcG2b4YmzxzZaWCZDIS1VFAHSY_kUYJMGpKs9_WTQfwr62nmcKXyLrf9NbrMFSesmiGzusNmmGsEuEpTG7IVV9wUa5ebN priority: 102 providerName: Scholars Portal |
Title | Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32681007 https://www.proquest.com/docview/2424566917/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC7368038 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB2SlEIvpd_ZNl106K0oG1v-kI5tmhAKG0JJYW_GkkZkoesNawean5B_3RnZXrLtrRdfLMnGb-R5g2beAHxKApGKNHWydGUts9znUhMLkSornA5oSoyKN_PL4uJn9n2RL_YgH2thYtK-s8vj5tfquFnexNzK25WbjXlis6v5aakKfaL0bB_2S6Uehei9oHdqssQMBTI8rCUnxYVkHChp8reSxaeJtmjOENj1R_-QzL9zJR85n_MX8HxgjeJL_3YvYQ-bV_C07yN5_xoevkXyx2G_4KKwdrnhiihR23a9sejFhhUIGALRrQVRPsEqEbS5GxrDTcJFvaOhK9YhTrlbSfLrwi_dDSfqeRREccU2N52H2TWtscKuJpbZYvsGrs_Prk8v5NBjQbq8NJ1MDfokRO0lVXAD0ZCZUHiKC1HlAZGbU2NirC0Sq43TuQul8cGq2uqQ5uotHDT0oEMQdYKeCJR3J0gsB1NTewJcIz2A_iEOJ_B5_NDVba-kUcUTcKWrHqGKEKoiQtXvCRyNWFTDrmqrNB7TFhRhTuBdD8t2qRHPCZQ7gG0HsI727h0yr6inPZjT-_-e-QGepWxdUW_zCA66zR1-JK7S2SlZ6KKcwpOvZ5dXP6Yx4qfrPNPTaLV_ABEe8Iw |
link.rule.ids | 230,315,733,786,790,870,891,12083,21416,24346,27957,27958,31754,33779,43345,43840,53827,53829,74102,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwELUoqCqXqvSLLZT60BuyIHES26cKtUVbvk6LtDcrtsdiD2zoJkjwE_jXnXGy224r9RzHjvJsz7Nn5g1jn7OIpCLPvVBe1aIoQyk0shAhi8rrCEZBUry5vKrG18XZtJwOF27tEFa53BPTRh0aT3fkR3ly0VV4uvhy91NQ1Sjyrg4lNJ6xrULKgkL61FSt7ljIi1VkZsiVOZb6qEV7RTlldGbSaHrFw7o9-odk_h0r-YfxOX3FXg6skZ_0MO-wDZi_Zs_7OpKPb9jTt0T-6NjPKSmsnS0oI4rXrm0WDgJfkAIBQcC7hiPl46QSgYt7jm2oSDiv1zR0eRPTK_e3Au06DzN_Q4F6AThSXL6KTadmrsE-bqGrkWW20L5lk9Pvk69jMdRYEL5UphO5gZDFpL0kKyogGgsTq4DnQpBlBKDi1JAZ56rMaeN16aMyITpZOx3zUr5jm3McaJfxOoOABCr4Y0CWA7mpAwKuAQfAPcTDiB0uf7S965U0bPKAS217WCzCYhMs9mHE9pdY2GFVtfb3HBix9z0sq66QhmqK-BgxtQbYqgHpaK8_mc9ukp62kpXGr_jw_yE_sRfjyeWFvfhxdb7HtnOaQ0lgc59tdot7-IjkpHMHaQb-AoFz5jc |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BEYgLKu-FFnzghqzdPG2fEKKsWh4VhyLtzYrtsbqHbsomlcpP4F8z42SXLkic49hRvrHns2f8DcCbLBKpyHMvlVeNLKtQSU0sRBZl7XVEozAp3nw9rY-_l58W1WLMf-rGtMrNmpgW6tB6PiOf5ilEV9PuYhrHtIhvR_N3lz8kV5DiSOtYTuM23CEvOeNqBmqhtuctHNEqMzPem5kVetqR7-L7Zbx_0uSG5fWub_qHcP6dN3nDEc334cHIIMX7AfKHcAtXj-DuUFPy52P4dZSIIB8BCL4g1i3XfDtKNK5r1w6DWLMaAcMh-lYQ_ROsGEETfUVtuGC4aHb0dEUb0ytXF5J8vAhLf85JewEF0V2xzVPnZq6lPi6wb4hxdtg9gbP5x7MPx3KstyB9pUwvc4Mhi0mHqai5mGgsTawD7RGxqCIiF6rGzDhXZ04brysflQnRFY3TMa-Kp7C3ooGeg2gyDESmgp8hMR7MTRMIfI00AK0nHifwdvOj7eWgqmFTNLzQdoDFEiw2wWKvJ3CwwcKOM6yzf-xhAs8GWLZdESXVnP0xAbUD2LYBa2rvPlktz5O2tipqTV_x4v9DvoZ7ZHz2y8np55dwP2cTSlqbB7DXr6_wkHhK714lA_wN6JPqYw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreasing+undesirable+absorbed+radiation+to+the+intestine+after+administration+of+radium-223+dichloride+for+treatment+of+bone+metastases&rft.jtitle=Scientific+reports&rft.au=Ogawa+Kazuma&rft.au=Higashi+Takuma&rft.au=Mishiro+Kenji&rft.au=Wakabayashi%2C+Hiroshi&rft.date=2020-07-17&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-020-68846-x&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |